The company's product lines include radiofrequency ablation systems, embolization products for treating tumors, and surgical resection systems, such as the NanoKnife Ablation System. AngioDynamics' Vascular segment targets the venous intervention, thrombus management, dialysis access, and peripheral disease markets, while the Oncology/Surgery segment is responsible for the RF Ablation, embolization, Habib, and NanoKnife product lines. The company generates most of its revenue from Endovascular Therapies and primarily operates in the United States. AngioDynamics aims to improve patients' quality of life by restoring healthy blood flow and expanding cancer treatment options through innovative medical technologies and devices.